RxDoctor Payments Data

Kai Jones, MD

Endocrinology, Diabetes & Metabolism · Saint Louis, MONPI 1427618578

Payments from drug & device makers

$3,901in general payments, 2019–2025

Across 12 payments — averaging $325.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$3K
  • BETA Bionics, Inc.$323
  • Lilly USA, LLC$147
  • Medtronic$125
  • Tandem Diabetes Care, Inc.$115
  • Sanofi-aventis U.S. LLC$78
  • plus $103 from 3 others

What the payments were for

  • Consulting fees$2,82072%
  • Food & beverage$1,08128%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,901 in reported general payments places this provider in the 60th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

See all endocrinology, diabetes & metabolism providers in Missouri

Medicare billing

Part B allowed, 2024
$16,872
Medicare patients
49
Services billed
413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$108,919
MounjaroTirzepatide58$64,088
JardianceEmpagliflozin39$43,611
TrulicityDulaglutide21$20,512
FarxigaDapagliflozin Propanediol13$10,735
Gvoke Hypopen 2-PackGlucagon13$8,513
JanuviaSitagliptin Phosphate12$7,973
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$4,271
Rosuvastatin Calcium13$1,879
SynthroidLevothyroxine Sodium12$1,143
Hydrocortisone21$576
Levothyroxine Sodium41$294
Metformin Hcl ErMetformin Hcl12$251
Ezetimibe17$163
Atorvastatin Calcium15$128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$71$108,91959 claims
Lilly USA, LLCMounjaro, Trulicity$147$84,59979 claims
Boehringer IngelheimJardiance$17$43,61139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

Other endocrinology, diabetes & metabolism in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →